Two bobs worth for what it is worth...
Point 1 : Agree with this assumption that is how they operate around here...false flags lol. Seriously though given the time to get the whole telehealth schebang around respiratory diagnosis I reckon you should be worrying about how it all sits and gels in 12 months from now...up front payment is still money and goes toward revenue...same as R&D money.
Point 2 : It seems to me that same as Dx is going to be spun out there any Covid screening/diagnosis test would be spun out there the same way...via telehealth platforms. They have the tech and the penetration and the ability to upgrade to a serious series of confirming tests and prescriptions if required.
I reckon telehealth platforms are going to be the interface between the patient and the RAP tech/testing/diagnostic and that is where the revenue will mainly be earned.
Don't dismiss al the other irons that RAP has in the fire...go check Bentley's posts they will give you the heads up. Otherwise if you are in fear then that is a choice...thoughts create reality...stay away from fear is my humble advice. After all nothing matters
- Forums
- ASX - By Stock
- RAP
- Ann: Cough analysis patent granted in China
Ann: Cough analysis patent granted in China, page-83
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online